On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Medscape Medical News, December 18, 2024 Alert ‘Game Changer’ Approved for Congenital Adrenal Hyperplasia The US Food and Drug Administration has approved crinecerfont for treating congenital ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard therapy is more efficacious for providing a complete renal response than ...

In response, scientists have spent years searching for a safer alternative. That’s where crinecerfont, the active ingredient in Crenessity, comes in. Before the first prescription could be ...

Speiser was a consultant to Neurocrine Biosciences and was a principal investigator in the pediatric trial for crinecerfont (Crenessity). The insights shared here represent her knowledge as a med ...

Growth disorders are disorders that affect the patient's height, weight and sexual development. These disorders are typically the result of atypical levels of growth hormone and patients can have ...

Neurocrine's pipeline represents a critical component of its future growth strategy. The company is awaiting FDA decisions on crinecerfont for congenital adrenal hyperplasia (CAH), with PDUFA dates ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH).

Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained Breakthrough ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH). In addition to Ingrezza, Neurocrine’s diverse portfolio contains other ...